(Q50251062)

28 February 2018

title

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. (English)

1 reference

28 February 2018

author name string

Alison M Schram

1

1 reference

28 February 2018

Matthew T Chang

2

1 reference

28 February 2018

Philip Jonsson

3

1 reference

28 February 2018

Alexander Drilon

4

1 reference

28 February 2018

language of work or name

English

0 references

publication date

31 August 2017

1 reference

28 February 2018

Nature Reviews Clinical Oncology

published in

1 reference

28 February 2018

volume

14

1 reference

28 February 2018

page(s)

735-748

1 reference

28 February 2018

issue

12

1 reference

28 February 2018

The landscape of kinase fusions in cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The impact of translocations and gene fusions on cancer causation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The emerging complexity of gene fusions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Immunological method for mapping genes on Drosophila polytene chromosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Advances in understanding cancer genomes through second-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

RNA sequencing: advances, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The landscape and therapeutic relevance of cancer-associated transcript fusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Identification of targetable FGFR gene fusions in diverse cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Tyrosine kinase gene rearrangements in epithelial malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Landscape of gene fusions in epithelial cancers: seq and ye shall find

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Demystified molecular pathology of NUT midline carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The resurgence of covalent drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The oncogene ERG: a key factor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Molecular pathways: ROS1 fusion proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Dermatofibrosarcoma protuberans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

TRKing down an old oncogene in a new era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Transforming fusions of FGFR and TACC genes in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Cytogenetics of a renal adenocarcinoma in a 2-year-old child

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

6q- and loss of the Y chromosome--two common deviations in malignant human salivary gland tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

LG-25PEDIATRIC LOW-GRADE GLIOMAS WITH CRAF GENE FUSIONS RESPOND DIFFERENTIALLY TO TARGETED THERAPEUTICS BASED ON DIMERIZATION PROFILES.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

inferred from DOI database lookup

7 January 2021

based on heuristic

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.127

inferred from DOI database lookup

7 January 2021

based on heuristic

High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28857077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2017.127

1 reference

28 February 2018

PubMed ID

28857077

1 reference

28 February 2018